FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204287564> ?p ?o ?g. }

• W3204287564 endingPage "e049858" @default.
• W3204287564 startingPage "e049858" @default.
• W3204287564 abstract "Introduction There is currently only one approved medication effective at improving walking distance in people with intermittent claudication. Preclinical data suggest that the β 3 -adrenergic receptor agonist (mirabegron) could be repurposed to treat intermittent claudication associated with peripheral artery disease. The aim of the Stimulating β 3 -Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial is to test whether mirabegron improves walking distance in people with intermittent claudication. Methods and analysis The STAR-PAD trial is a Phase II, multicentre, double-blind, randomised, placebo-controlled trial of mirabegron versus placebo on walking distance in patients with PAD. A total of 120 patients aged ≥40 years with stable PAD and intermittent claudication will be randomly assigned (1:1 ratio) to receive either mirabegron (50 mg orally once a day) or matched placebo, for 12 weeks. The primary endpoint is change in peak walking distance as assessed by a graded treadmill test. Secondary endpoints will include: (i) initial claudication distance; (ii) average daily step count and total step count and (iii) functional status and quality of life assessment. Mechanistic substudies will examine potential effects of mirabegron on vascular function, including brachial artery flow-mediate dilatation; MRI assessment of lower limb blood flow, tissue perfusion and arterial stiffness and numbers and angiogenesis potential of endothelial progenitor cells. Given that mirabegron is safe and clinically available for alternative purposes, a positive study is positioned to immediately impact patient care. Ethics and dissemination The STAR-PAD trial is approved by the Northern Sydney Local Health District Human Research Ethics Committee (HREC/18/HAWKE/50). The study results will be published in peer-reviewed medical or scientific journals and presented at scientific meetings, regardless of the study outcomes. Trial registration number ACTRN12619000423112; Results." @default.
• W3204287564 created "2021-10-11" @default.
• W3204287564 creator A5001527769 @default.
• W3204287564 creator A5004208421 @default.
• W3204287564 creator A5007659883 @default.
• W3204287564 creator A5010661645 @default.
• W3204287564 creator A5011046660 @default.
• W3204287564 creator A5011948462 @default.
• W3204287564 creator A5012111658 @default.
• W3204287564 creator A5014914458 @default.
• W3204287564 creator A5015358492 @default.
• W3204287564 creator A5017104699 @default.
• W3204287564 creator A5045116934 @default.
• W3204287564 creator A5053726243 @default.
• W3204287564 creator A5056426820 @default.
• W3204287564 creator A5063550687 @default.
• W3204287564 creator A5076250987 @default.
• W3204287564 creator A5087169102 @default.
• W3204287564 date "2021-09-01" @default.
• W3204287564 modified "2023-10-06" @default.
• W3204287564 title "Protocol for the Stimulating β₃-Adrenergic Receptors for Peripheral Artery Disease (STAR-PAD) trial: a double-blinded, randomised, placebo-controlled study evaluating the effects of mirabegron on functional performance in patients with peripheral arterial disease" @default.
• W3204287564 cites W1863568658 @default.
• W3204287564 cites W188696429 @default.
• W3204287564 cites W1933409166 @default.
• W3204287564 cites W1971651222 @default.
• W3204287564 cites W2027009674 @default.
• W3204287564 cites W2032517479 @default.
• W3204287564 cites W2034203772 @default.
• W3204287564 cites W2046861835 @default.
• W3204287564 cites W2050474359 @default.
• W3204287564 cites W2062768688 @default.
• W3204287564 cites W2063506869 @default.
• W3204287564 cites W2074697641 @default.
• W3204287564 cites W2082352316 @default.
• W3204287564 cites W2095219849 @default.
• W3204287564 cites W2110101054 @default.
• W3204287564 cites W2122479313 @default.
• W3204287564 cites W2122791124 @default.
• W3204287564 cites W2123874951 @default.
• W3204287564 cites W2133124389 @default.
• W3204287564 cites W2141665762 @default.
• W3204287564 cites W2144985796 @default.
• W3204287564 cites W2150148660 @default.
• W3204287564 cites W2172174230 @default.
• W3204287564 cites W2287138970 @default.
• W3204287564 cites W2549031161 @default.
• W3204287564 cites W2583368120 @default.
• W3204287564 cites W2618042426 @default.
• W3204287564 cites W2794395956 @default.
• W3204287564 cites W2807269838 @default.
• W3204287564 cites W2896002881 @default.
• W3204287564 cites W2903419478 @default.
• W3204287564 cites W2973825900 @default.
• W3204287564 cites W3158655061 @default.
• W3204287564 cites W4241453607 @default.
• W3204287564 doi "https://doi.org/10.1136/bmjopen-2021-049858" @default.
• W3204287564 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8479946" @default.
• W3204287564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34588252" @default.
• W3204287564 hasPublicationYear "2021" @default.
• W3204287564 type Work @default.
• W3204287564 sameAs 3204287564 @default.
• W3204287564 citedByCount "4" @default.
• W3204287564 countsByYear W32042875642022 @default.
• W3204287564 countsByYear W32042875642023 @default.
• W3204287564 crossrefType "journal-article" @default.
• W3204287564 hasAuthorship W3204287564A5001527769 @default.
• W3204287564 hasAuthorship W3204287564A5004208421 @default.
• W3204287564 hasAuthorship W3204287564A5007659883 @default.
• W3204287564 hasAuthorship W3204287564A5010661645 @default.
• W3204287564 hasAuthorship W3204287564A5011046660 @default.
• W3204287564 hasAuthorship W3204287564A5011948462 @default.
• W3204287564 hasAuthorship W3204287564A5012111658 @default.
• W3204287564 hasAuthorship W3204287564A5014914458 @default.
• W3204287564 hasAuthorship W3204287564A5015358492 @default.
• W3204287564 hasAuthorship W3204287564A5017104699 @default.
• W3204287564 hasAuthorship W3204287564A5045116934 @default.
• W3204287564 hasAuthorship W3204287564A5053726243 @default.
• W3204287564 hasAuthorship W3204287564A5056426820 @default.
• W3204287564 hasAuthorship W3204287564A5063550687 @default.
• W3204287564 hasAuthorship W3204287564A5076250987 @default.
• W3204287564 hasAuthorship W3204287564A5087169102 @default.
• W3204287564 hasBestOaLocation W32042875641 @default.
• W3204287564 hasConcept C126322002 @default.
• W3204287564 hasConcept C141071460 @default.
• W3204287564 hasConcept C142724271 @default.
• W3204287564 hasConcept C164705383 @default.
• W3204287564 hasConcept C1862650 @default.
• W3204287564 hasConcept C203092338 @default.
• W3204287564 hasConcept C204787440 @default.
• W3204287564 hasConcept C27081682 @default.
• W3204287564 hasConcept C2777466421 @default.
• W3204287564 hasConcept C2778164427 @default.
• W3204287564 hasConcept C2778941218 @default.
• W3204287564 hasConcept C2778963770 @default.
• W3204287564 hasConcept C2779881954 @default.
• W3204287564 hasConcept C3018348675 @default.
• W3204287564 hasConcept C535046627 @default.
• W3204287564 hasConcept C71924100 @default.

• next